Skin as an immune organ  by Chu, Chia-Yu
at SciVerse ScienceDirect
DERMATOLOGICA SINICA 30 (2012) 119–120Contents lists availableDermatologica Sinica
journal homepage: http: / /www.derm-sinica.comEDITORIAL VIEW
Skin as an immune organOver the past 20 years, the discovery that keratinocytes are
immunologically active cells has reinforced the concept that the
skin is an active immune organ.1 It is clear that the epidermis can
function as an immunologic tissue. This is critically important to
its function as a barrier to external toxins and microbes. Moreover,
recent ﬁndings on the roles of antimicrobial peptides, Toll-like
receptors, antigen-presenting cells, regulatory T (Treg), and
interleukin-17 (IL-17)-producing T helper (Th17) cells in maintain-
ing the skin functions and leading to various skin disorders also
encourage the development of immunologically active biologic
therapies for skin diseases. In this special issue, important recent
ﬁndings on skin immunity are comprehensively reviewed by the
experts.
Galectins are a family of lectins containing one or two conserved
carbohydrate-recognition domains that preferentially bind to b-
galactosides.2 Galectins may work extracellularly in an autocrine
or paracrine manner to modulate cell status or functions, e.g., acti-
vation of cells, mediation of cell–cell/cell–extracellular matrix
interactions, and promotion of cell migration.2 Intracellularly,
galectins can function in a carbohydrate-independent manner to
regulate cell apoptosis, migration, and responses to stimuli.3
Several galectins such as galectin-1, -3, and -9 have been found to
be important regulators in cutaneous immune disorders. In this
issue, Chen et al review the importance of galectins in cutaneous
immunity and skin diseases, especially contact dermatitis, psori-
asis, and atopic dermatitis (AD).4
Chemokines are structurally related, small (8–14 kDa) polypep-
tide signaling molecules that bind to and activate a family of seven
transmembrane G protein-coupled receptors, the chemokine
receptors.5 Chemokines are known for their ability to stimulate
the directional migration of all classes of leukocytes.5 In the skin,
chemokines from various skin cells mediate trafﬁcking of different
subsets of inﬂammatory cells to bind to the corresponding chemo-
kine receptors, forming a pro-inﬂammatory response. In this
special issue, Lee and Hwang examine two diseases as examples
where the roles for chemokines and their receptors have been
demonstrated through human and experimental animal studies.6
The understanding of how chemokine receptors participate in
various skin disorders provides a promising rationale for the use
of receptor inhibitors or anti-chemokine receptor antibodies as
novel therapeutic agents.
The recent discovery of the roles of Th17 cells in the pathogen-
esis of psoriasis is a major breakthrough in psoriasis management.
Activated dendritic cells produce cytokines, including IL-23, IL-12,
and tumor necrosis factor (TNF)-a, and drive naïve T cells to1027-8117/$ – see front matter Copyright  2012, Taiwanese Dermatological Associatio
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growth factor (TGF)-b and IL-6.7 Th17 cells produce IL-17, IL-22,
and have other important downstream pro-inﬂammatory effects
in skin. Clinically, expression of Th17-related cytokines is markedly
increased in psoriatic lesions, and successful therapy is associated
with restoration of the expression of Th17-associated genes to
near-normal levels.8 A summary of the current knowledge about
Th17 cells and new therapeutic agents targeting the effector func-
tions of Th17 cells for psoriasis is also presented in this special
issue.8
AD is a chronic relapsing skin disease characterized by eczema-
tous skin lesions and intense pruritus. It is one of the most frequent
chronic inﬂammatory skin diseases, affecting at least 15% of chil-
dren and 2–10% of adults in industrialized countries and its preva-
lence appears to be increasing.9 There is a long debate around what
is the primary cause of AD, the barrier dysfunction or the allergy/
immunology abnormalities. Recently, the discovery of a link
between the incidence of AD and loss-of-function mutations in
the gene encoding ﬁlaggrin suggests that barrier dysfunction occurs
ﬁrst, followed by allergy/immunology abnormalities.10 The atopic
inﬂammatory response can induce an acquired barrier defect to
create a positive feedback loop by acting in a highly interdisci-
plinary manner in the development of AD.10 In this scenario, epicu-
taneous (EC) sensitization of protein antigens, which induces
predominant Th2, marginal Th1, and signiﬁcant Th17 and Treg
responses, might be one of the important routes of allergen sensi-
tization for AD.11 It has been shown that EC sensitizationwith oval-
bumin induced a predominant Th2 and a marginal Th1 response
with high immunoglobulin E (IgE) production in mice.12 EC sensiti-
zation with house dust mite Ag was also shown to elicit a Th2-
dominant cytokine response.13 It is common to ﬁnd adult AD
patients with serum IgE even higher than 10,000 IU/mL.14 Omalizu-
mab, designed to bind to free IgE but not to IgE bound by the high-
afﬁnity IgE.Fc receptors (FcεRI) on mast cells and basophils, can
neutralize IgE and block IgE binding to FcεRI.15 Omalizumab has
been approved in the USA, the European Union, and many other
regions for the treatment of patients 12 years and older with
moderate-to-severe or severe allergic asthma.15 However, its role
in treating AD is still controversial. In the past several years,
many reports investigating the therapeutic effects of omalizumab
in patients with moderate-to-severe or severe AD have been pub-
lished.16 Based on the above observations, Chen et al proposed
a novel pharmacological mechanism in omalizumab in which the
rapidly accumulated IgE:anti-IgE immune complexes may trap
allergens.16,17 Whether this effect is present in high-IgE patientsn. Published by Elsevier Taiwan LLC. All rights reserved.
Editorial view / Dermatologica Sinica 30 (2012) 119–120120with AD needs further investigation in order to provide the theoret-
ical basis for using omalizumab for the treatment of this disease.
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